Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2025; 14(01): 038-044
DOI: 10.1055/s-0044-1789582
Original Article
Breast Cancer

Tumor Budding: A Novel Prognostic Marker in Breast Carcinoma with Correlation of Histopathological and Immunohistochemical Parameters

Poornima Manimaran
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Ashini Shah
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Amisha Gami
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Jahnavi Gandhi
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Sneha Kakoty
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Varnika Rai
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
,
Priti P. Trivedi
1   Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction

Breast cancer is a highly heterogenous tumor with different subtypes showing varying prognosis. Tumor budding is an unfavorable histological feature of many epithelial cancers. The purpose of this study is to analyze the association between tumor bud density with various histological and immunohistochemical characteristics and to explore its prognostic role in breast carcinoma.

Materials and Methods

A retrospective analysis was performed on 100 patients of breast cancer diagnosed in our institute from January to December 2017. Hematoxylin and eosin (H&E) stained slides from tumors and immunohistochemical slides were reviewed independently by two pathologists, and clinical data were acquired from computerized records. Patients on neoadjuvant chemotherapy were excluded from the study.

Results

The study comprised 100 patients of invasive breast carcinoma. The median age was 52 years, and 96% were invasive ductal carcinoma. The median follow-up was 34 months. High tumor bud density was substantially correlated with primary tumor staging (T3, T4; 73% [11/15] cases) and lymph node staging (N2, N3; 68% [13/19] cases) with p-values of 0.017 and 0.023, respectively. Systemic metastasis (85% [6/7] cases) was significantly associated with high tumor bud density (p =0.025) but lymphovascular invasion (LVI) and perineural invasion (PNI) were not significantly associated with tumor bud density (p = 0.762 and 0.862, respectively). Patients with N2 nodal stage had low event-free survival rate than N0/N1 nodal stage irrespective of tumor bud status. Grade 3 tumors with high tumor bud density had worse event-free survival than any other grades. There was no association of tumor bud density with tumor staging, necrosis, PNI, LVI, estrogen receptor (ER), progesterone receptor (PR) and Her2/neu, and event-free survival.

Conclusion

Strong relationships have been found between tumor bud density and poor prognostic variables such as primary tumor staging and lymph node staging. These results provide credence to the idea that tumor bud density can be an assessable prognostic feature that should be taken into account while reporting breast cancer cases. Tumor bud density evaluation has to be standardized nevertheless if it is to be widely adopted.

Keywords

breast carcinoma - event-free survival - Her2/neu - hormone receptors - tumor bud


Publication History

Received: 13 August 2023

Accepted: 29 July 2024

Article published online:
28 August 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (01) 7-30
    CrossrefPubMedSearch in Google Scholar
  • 2 Agarwal R, Khurana N, Singh T, Agarwal PN. Tumor budding in infiltrating breast carcinoma: correlation with known clinicopathological parameters and hormone receptor status. Indian J Pathol Microbiol 2019; 62 (02) 222-225
    CrossrefPubMedSearch in Google Scholar
  • 3 Imai T. Growth patterns in human carcinoma. Their classification and relation to prognosis. Obstet Gynecol 1960; 16: 296-308
    PubMedSearch in Google Scholar
  • 4 Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract 2013; 209 (05) 269-275
    CrossrefPubMedSearch in Google Scholar
  • 5 Huang T, Bao H, Meng YH. et al. Tumour budding is a novel marker in breast cancer: the clinical application and future prospects. Ann Med 2022; 54 (01) 1303-1312
    CrossrefPubMedSearch in Google Scholar
  • 6 Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tumor budding: the name is EMT. Partial EMT. J Clin Med 2016; 5 (05) 51
    CrossrefPubMedSearch in Google Scholar
  • 7 Lugli A, Kirsch R, Ajioka Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 2017; 30 (09) 1299-1311
    CrossrefPubMedSearch in Google Scholar
  • 8 Rathod GB, Desai KN, Shrivastava A, Maru AM. Correlation of tumor budding with known clinicopathological, histomorphological and hormonal receptor status in patients with invasive breast carcinoma. Cureus 2022; 14 (09) e29637
    PubMedSearch in Google Scholar
  • 9 Voutsadakis IA. Prognostic role of tumor budding in breast cancer. World J Exp Med 2018; 8 (02) 12-17
    CrossrefPubMedSearch in Google Scholar
  • 10 Kumarguru BN, Ramaswamy AS, Shaik S, Karri A, Srinivas VS, Prashant BM. Tumor budding in invasive breast cancer: an indispensable budding touchstone. Indian J Pathol Microbiol 2020; 63 (Supplement): S117-S122
    CrossrefPubMedSearch in Google Scholar
  • 11 Salhia B, Trippel M, Pfaltz K. et al. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat 2015; 150 (02) 363-371
    CrossrefPubMedSearch in Google Scholar
  • 12 Kundu T, Giri R, Hota SK, Sahu SK, Senapati U. Tumour budding in invasive breast carcinoma and its correlation with histopathological prognostic parameters and hormone receptor status. J Cancer Res Ther 2023; 19 (Suppl. 02) S664-S668
    CrossrefPubMedSearch in Google Scholar
  • 13 Masilamani S, Kanmani P. Evaluation of clinicopathologic significance of tumor budding in breast carcinoma. Int J Clin Diagn Pathol 2019; 2: 171-173
    CrossrefSearch in Google Scholar
  • 14 Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer 2015; 113 (07) 1066-1074
    CrossrefPubMedSearch in Google Scholar
  • 15 Renuka IV, Madhavi K, Premalatha P, Krishnamacharyulu PAV, Vaishnavi R. Tumor budding in invasive carcinoma of breast of no special type (NST): value as a prognostic factor. IP J Diagn Pathol Oncol 2019; 4: 125-129
    CrossrefSearch in Google Scholar
  • 16 Singh T, Chandra K, Kumar N. et al. A retrospective study of association of tumor budding, tumor microenvironment, and clinicopathological characteristics of invasive breast carcinoma. J Lab Physicians 2022; 14 (04) 485-490
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Patel M, Gupta V. Evaluation of prognostic role of tumour budding in breast carcinoma and its correlation with known clinicopathological parameters. Indian Pathol Oncol 2022; 9: 238-242
    CrossrefSearch in Google Scholar
  • 18 Xiang Z, He Q, Huang L, Xiong B, Xiang Q. Breast cancer classification based on tumor budding and stem cell-related signatures facilitate prognosis evaluation. Front Oncol 2022; 11: 818869
    CrossrefPubMedSearch in Google Scholar
  • 19 Lloyd AJ, Ryan ÉJ, Boland MR. et al. The histopathological and molecular features of breast carcinoma with tumour budding-a systematic review and meta-analysis. Breast Cancer Res Treat 2020; 183 (03) 503-514
    CrossrefPubMedSearch in Google Scholar